Serum Calprotectin Level as an Inflammatory Marker in Newly Diagnosed Hypertensive Patients
Open Access
- 21 January 2022
- journal article
- research article
- Published by Hindawi Limited in International Journal of Hypertension
- Vol. 2022, 1-7
Abstract
Background. Hypertension is one of the leading causes of cardiovascular mortality. Although the pathogenetic process involved is not yet fully understood, the disease involves endothelial damage and inflammation. Calprotectin is an inflammatory marker that rises in parallel with disease activity in conditions such as systemic inflammatory diseases, infection, and atherosclerosis. The purpose of this study was to evaluate inflammation through serum calprotectin levels in newly diagnosed primary hypertension patients. Methods. Forty-nine newly diagnosed hypertensive patients and 38 healthy adults were included in the study. Patients’ office blood pressure values, biochemical findings, and demographic characteristics were recorded. Serum calprotectin levels were measured using ELISA. Parameters affecting serum calprotectin levels and determinants of hypertension were evaluated. Results. Serum calprotectin levels were 242.8 (72.4–524) ng/mL in the control group and 112.6 (67.4–389.8) ng/mL in the hypertensive patient group, the difference being statistically significant ( ). There was no correlation between serum calprotectin levels and other parameters (blood pressure values, age, gender, serum creatinine, uric acid, and calcium levels) in the hypertensive group. A lower serum calprotectin level was found to be independently related to hypertension (β = −0.009, ). Serum calprotectin at a cutoff level of 128.6 ng/mL differentiated hypertensives from healthy controls with a sensitivity of 69.4% and specificity of 68.4% (AUC = 0.767). Conclusions. The results of this study were the opposite of our hypothesis that a higher calprotectin level may reflect subclinical endothelial damage in newly diagnosed hypertensive patients. Further comparative studies involving patients at different stages of hypertension may contribute to clarifying the relationship between calprotectin and hypertension. We conclude that molecular studies seem essential for understanding the place of calprotectin in hypertension-associated inflammation, a complex process.Keywords
This publication has 39 references indexed in Scilit:
- Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertensionJournal Of Hypertension, 2009
- Myeloid-Related Protein-8/14 Is Critical for the Biological Response to Vascular InjuryCirculation, 2009
- Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable anginaHeart, 2008
- Calcium-dependent Tetramer Formation of S100A8 and S100A9 is Essential for Biological ActivityJournal of Molecular Biology, 2006
- S100A8 and S100A9 in Human Arterial WallJournal of Biological Chemistry, 2005
- Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophilsJournal of Leukocyte Biology, 2004
- Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air‐pouch model of acute gouty arthritisArthritis & Rheumatism, 2003
- Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?Hypertension, 2003
- The S100 Family Heterodimer, MRP-8/14, Binds with High Affinity to Heparin and Heparan Sulfate Glycosaminoglycans on Endothelial CellsJournal of Biological Chemistry, 2002
- Functional and clinical aspects of the myelomonocyte protein calprotectin.Molecular Pathology, 1997